![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: HECW2 |
Gene summary for HECW2 |
![]() |
Gene information | Species | Human | Gene symbol | HECW2 | Gene ID | 57520 |
Gene name | HECT, C2 and WW domain containing E3 ubiquitin protein ligase 2 | |
Gene Alias | NDHSAL | |
Cytomap | 2q32.3 | |
Gene Type | protein-coding | GO ID | GO:0000070 | UniProtAcc | A0A2C9F2N4 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
57520 | HECW2 | ATC11 | Human | Thyroid | ATC | 1.80e-12 | 8.48e-01 | 0.3386 |
57520 | HECW2 | ATC12 | Human | Thyroid | ATC | 1.13e-11 | 2.47e-01 | 0.34 |
57520 | HECW2 | ATC3 | Human | Thyroid | ATC | 2.42e-14 | 7.06e-01 | 0.338 |
57520 | HECW2 | ATC4 | Human | Thyroid | ATC | 3.34e-18 | 3.50e-01 | 0.34 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001049832 | Thyroid | ATC | proteasomal protein catabolic process | 309/6293 | 490/18723 | 1.78e-41 | 1.13e-37 | 309 |
GO:0043161210 | Thyroid | ATC | proteasome-mediated ubiquitin-dependent protein catabolic process | 265/6293 | 412/18723 | 7.09e-38 | 1.49e-34 | 265 |
GO:0009896210 | Thyroid | ATC | positive regulation of catabolic process | 290/6293 | 492/18723 | 2.15e-31 | 1.94e-28 | 290 |
GO:004217635 | Thyroid | ATC | regulation of protein catabolic process | 239/6293 | 391/18723 | 2.63e-29 | 1.85e-26 | 239 |
GO:0045732210 | Thyroid | ATC | positive regulation of protein catabolic process | 148/6293 | 231/18723 | 1.93e-21 | 4.36e-19 | 148 |
GO:014001416 | Thyroid | ATC | mitotic nuclear division | 171/6293 | 287/18723 | 1.13e-19 | 1.66e-17 | 171 |
GO:003304423 | Thyroid | ATC | regulation of chromosome organization | 119/6293 | 187/18723 | 3.55e-17 | 3.40e-15 | 119 |
GO:004477219 | Thyroid | ATC | mitotic cell cycle phase transition | 223/6293 | 424/18723 | 3.46e-16 | 2.88e-14 | 223 |
GO:000007013 | Thyroid | ATC | mitotic sister chromatid segregation | 108/6293 | 168/18723 | 3.53e-16 | 2.90e-14 | 108 |
GO:000734622 | Thyroid | ATC | regulation of mitotic cell cycle | 236/6293 | 457/18723 | 7.58e-16 | 5.92e-14 | 236 |
GO:000081913 | Thyroid | ATC | sister chromatid segregation | 122/6293 | 202/18723 | 4.71e-15 | 3.17e-13 | 122 |
GO:000705913 | Thyroid | ATC | chromosome segregation | 183/6293 | 346/18723 | 8.03e-14 | 4.23e-12 | 183 |
GO:0000209110 | Thyroid | ATC | protein polyubiquitination | 134/6293 | 236/18723 | 1.86e-13 | 9.20e-12 | 134 |
GO:190199015 | Thyroid | ATC | regulation of mitotic cell cycle phase transition | 156/6293 | 299/18723 | 2.19e-11 | 7.80e-10 | 156 |
GO:005198311 | Thyroid | ATC | regulation of chromosome segregation | 60/6293 | 91/18723 | 2.83e-10 | 8.10e-09 | 60 |
GO:009881312 | Thyroid | ATC | nuclear chromosome segregation | 145/6293 | 281/18723 | 3.06e-10 | 8.61e-09 | 145 |
GO:003007111 | Thyroid | ATC | regulation of mitotic metaphase/anaphase transition | 44/6293 | 60/18723 | 3.54e-10 | 9.86e-09 | 44 |
GO:000709111 | Thyroid | ATC | metaphase/anaphase transition of mitotic cell cycle | 45/6293 | 62/18723 | 3.93e-10 | 1.08e-08 | 45 |
GO:001097523 | Thyroid | ATC | regulation of neuron projection development | 212/6293 | 445/18723 | 4.16e-10 | 1.14e-08 | 212 |
GO:004828512 | Thyroid | ATC | organelle fission | 229/6293 | 488/18723 | 4.79e-10 | 1.29e-08 | 229 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HECW2 | SNV | Missense_Mutation | rs775553074 | c.2205N>T | p.Glu735Asp | p.E735D | Q9P2P5 | protein_coding | tolerated_low_confidence(0.16) | possibly_damaging(0.527) | TCGA-67-4679-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
HECW2 | SNV | Missense_Mutation | c.1303N>T | p.Thr435Ser | p.T435S | Q9P2P5 | protein_coding | tolerated_low_confidence(0.95) | benign(0) | TCGA-69-7765-01 | Lung | lung adenocarcinoma | Male | <65 | III/IV | Chemotherapy | carboplatin | SD | |
HECW2 | SNV | Missense_Mutation | c.1214N>T | p.Arg405Met | p.R405M | Q9P2P5 | protein_coding | tolerated_low_confidence(0.22) | possibly_damaging(0.635) | TCGA-69-7979-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
HECW2 | SNV | Missense_Mutation | novel | c.4523A>G | p.Tyr1508Cys | p.Y1508C | Q9P2P5 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-73-A9RS-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | carboplatin | PD |
HECW2 | SNV | Missense_Mutation | c.1063N>A | p.Glu355Lys | p.E355K | Q9P2P5 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.981) | TCGA-78-7156-01 | Lung | lung adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD | |
HECW2 | SNV | Missense_Mutation | c.1095N>T | p.Gln365His | p.Q365H | Q9P2P5 | protein_coding | tolerated_low_confidence(0.19) | benign(0) | TCGA-78-7536-01 | Lung | lung adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD | |
HECW2 | SNV | Missense_Mutation | novel | c.2657N>T | p.Gly886Val | p.G886V | Q9P2P5 | protein_coding | tolerated(0.09) | benign(0.036) | TCGA-78-7540-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HECW2 | SNV | Missense_Mutation | c.2497A>T | p.Thr833Ser | p.T833S | Q9P2P5 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-86-7955-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | etoposide | PD | |
HECW2 | SNV | Missense_Mutation | c.1732A>G | p.Ser578Gly | p.S578G | Q9P2P5 | protein_coding | tolerated_low_confidence(0.28) | benign(0.003) | TCGA-86-7955-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | etoposide | PD | |
HECW2 | SNV | Missense_Mutation | novel | c.3050N>T | p.Arg1017Leu | p.R1017L | Q9P2P5 | protein_coding | deleterious(0.02) | probably_damaging(0.987) | TCGA-MN-A4N1-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |